 Seelos Therapeutics Inc NASDAQ: SEEL has announced data from Part 1, the open-label cohort, of its Proof-of-Concept study of SLS-002 for acute suicidal ideation and behavior in patients with Major Depressive Disorder. On depression scale, 76.5 response rate on Day 1 n17, 92.9 response rate on Day 16 n14 and 100 response rate on Day 29 n13 was observed. 